Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paul Takam Kamga is active.

Publication


Featured researches published by Paul Takam Kamga.


Scientific Reports | 2016

Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions.

Mariano Di Trapani; Giulio Bassi; Martina Midolo; Alessandro Gatti; Paul Takam Kamga; Adriana Cassaro; Roberta Carusone; Annalisa Adamo; Mauro Krampera

Mesenchymal stromal cells (MSCs) are multipotent cells, immunomodulatory stem cells that are currently used for regenerative medicine and treatment of a number of inflammatory diseases, thanks to their ability to significantly influence tissue microenvironments through the secretion of large variety of soluble factors. Recently, several groups have reported the presence of extracellular vesicles (EVs) within MSC secretoma, showing their beneficial effect in different animal models of disease. Here, we used a standardized methodological approach to dissect the immunomodulatory effects exerted by MSC-derived EVs on unfractionated peripheral blood mononuclear cells and purified T, B and NK cells. We describe here for the first time: i. direct correlation between the degree of EV-mediated immunosuppression and EV uptake by immune effector cells, a phenomenon further amplified following MSC priming with inflammatory cytokines; ii. induction in resting MSCs of immunosuppressive properties towards T cell proliferation through EVs obtained from primed MSCs, without any direct inhibitory effect towards T cell division. Our conclusion is that the use of reproducible and validated assays is not only useful to characterize the mechanisms of action of MSC-derived EVs, but is also capable of justifying EV potential use as alternative cell-free therapy for the treatment of human inflammatory diseases.


Oncotarget | 2016

Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia

Paul Takam Kamga; Giulio Bassi; Adriana Cassaro; Martina Midolo; Mariano Di Trapani; Alessandro Gatti; Roberta Carusone; Federica Resci; Omar Perbellini; Michele Gottardi; Massimiliano Bonifacio; Armel Herve Nwabo Kamdje; Achille Ambrosetti; Mauro Krampera

Both preclinical and clinical investigations suggest that Notch signalling is critical for the development of many cancers and for their response to chemotherapy. We previously showed that Notch inhibition abrogates stromal-induced chemoresistance in lymphoid neoplasms. However, the role of Notch in acute myeloid leukemia (AML) and its contribution to the crosstalk between leukemia cells and bone marrow stromal cells remain controversial. Thus, we evaluated the role of the Notch pathway in the proliferation, survival and chemoresistance of AML cells in co-culture with bone marrow mesenchymal stromal cells expanded from both healthy donors (hBM-MSCs) and AML patients (hBM-MSCs*). As compared to hBM-MSCs, hBM-MSCs* showed higher level of Notch1, Jagged1 as well as the main Notch target gene HES1. Notably, hBM-MSCs* induced expression and activation of Notch signalling in AML cells, supporting AML proliferation and being more efficientin inducing AML chemoresistance than hBM-MSCs*. Pharmacological inhibition of Notch using combinations of Notch receptor-blocking antibodies or gamma-secretase inhibitors (GSIs), in presence of chemotherapeutic agents, significant lowered the supportive effect of hBM-MSCs and hBM-MSCs* towards AML cells, by activating apoptotic cascade and reducing protein level of STAT3, AKT and NF-κB. These results suggest that Notch signalling inhibition, by overcoming the stromal-mediated promotion of chemoresistance,may represent a potential therapeutic targetnot only for lymphoid neoplasms, but also for AML.


Cancer biology and medicine | 2017

Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog

Armel Herve Nwabo Kamdje; Paul Takam Kamga; Richard Tagne Simo; Lorella Vecchio; Paul Faustin Seke Etet; Jean Marc Muller; Giulio Bassi; Erique Lukong; Raghuveera Kumar Goel; Jérémie Mbo Amvene; Mauro Krampera

Master developmental pathways, such as Notch, Wnt, and Hedgehog, are signaling systems that control proliferation, cell death, motility, migration, and stemness. These systems are not only commonly activated in many solid tumors, where they drive or contribute to cancer initiation, but also in primary and metastatic tumor development. The reactivation of developmental pathways in cancer stroma favors the development of cancer stem cells and allows their maintenance, indicating these signaling pathways as particularly attractive targets for efficient anticancer therapies, especially in advanced primary tumors and metastatic cancers. Metastasis is the worst feature of cancer development. This feature results from a cascade of events emerging from the hijacking of epithelial-mesenchymal transition, angiogenesis, migration, and invasion by transforming cells and is associated with poor survival, drug resistance, and tumor relapse. In the present review, we summarize and discuss experimental data suggesting pivotal roles for developmental pathways in cancer development and metastasis, considering the therapeutic potential. Emerging targeted antimetastatic therapies based on Notch, Wnt, and Hedgehog pathways are also discussed.


Blood | 2016

Role of Wnt/β-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy

Paul Takam Kamga; Adriana Cassaro; Giada Dal Collo; Annalisa Adamo; Alessandro Gatti; Roberta Carusone; Martina Midolo; Mariano Di Trapani; Federica Resci; Massimiliano Bonifacio; Mauro Krampera

Although drug-induced thrombotic microangiopathy (TMA) is commonly reported, evidence for a causal association is uncommonly documented. In this issue of Blood, Kavanagh et al use multiple methods to clearly establish a causal association of type I interferon with TMA.1


Oncotarget | 2018

MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways

Giorgio Malpeli; Stefano Barbi; Gabriele Tosadori; Corinna Greco; Simonetta Zupo; Serena Pedron; Matteo Brunelli; Anna Bertolaso; Maria Teresa Scupoli; Mauro Krampera; Paul Takam Kamga; Carlo M. Croce; George A. Calin; Aldo Scarpa; Alberto Zamò

In order to investigate the role of microRNAs in the pathogenesis of different B-cell lymhoma subtypes, we have applied an array-based assay to a series of 76 mixed non-Hodgkin B-cell lymphomas, including Burkitt’s lymphoma (BL), diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma (MCL) and follicular lymphoma. Lymphomas clustered according to histological subtypes, driven by two miRNA clusters (the miR-29 family and the miR-17-92 cluster). Since the two miRNA clusters are known to be MYC-regulated, we investigated whether this would be supported in MYC-driven experimental models, and found that this signature separated BL cell lines and a MYC-translocated MCL cell lines from normal germinal center B-cells and other B-cell populations. Similar results were also reproduced in tissue samples comparing BL and reactive lymph node samples. The same series was then quantitatively analyzed for MYC expression by immunohistochemistry and MYC protein levels were compared with corresponding miRNA signatures. A specific metric was developed to summarize the levels of MYC-related microRNAs and the corresponding protein levels. We found that MYC-related signatures are directly related to MYC protein expression across the whole spectrum of B-cells and B-cell lymphoma, suggesting that the MYC-responsive machinery shows predominantly quantitative, rather than qualitative, modifications in B-cell lymphoma. Novel MYC-related miRNAs were also discovered by this approach. Finally, network analysis found that in BL MYC-related differentially expressed miRNAs could control, either positively or negatively, a limited number of hub proteins, including BCL2, CDK6, MYB, ZEB1, CTNNB1, BAX and XBP1.


Oncotarget | 2018

Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway

Paul Takam Kamga; Giada Dal Collo; Giulio Bassi; Martina Midolo; Massimo Delledonne; Marco Chilosi; Massimiliano Bonifacio; Mauro Krampera

Notch signaling contribution to B-cell acute lymphoblastic leukemia (B-ALL) development is still under investigation. The serendipitous onset of B-ALL in a patient affected by the germinal Notch mutation-dependent Alagille syndrome allowed us to establish a B-ALL cell line (VR-ALL) bearing a genetic loss of function in components of Notch signaling. VR-ALL is a common-type B-ALL cell line, grows in conventional culture medium supplemented with 10% serum, and gives rise, once injected into immunodeficient NOG mice, to a mouse xenograft model of B-ALL. Exome sequencing revealed deleterious mutations in some components of Notch signaling, including Jagged1, Notch1, and Notch2. In addition, VR-ALL is sensitive both in vitro and in vivo to γ-secretase inhibitors (GSIs) as well as conventional anti-leukemic drugs. For all these reasons, VR-ALL may help to gain more insights into the role of Notch signaling in B-ALL.


Oncotarget | 2018

MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma

Giorgio Malpeli; Stefano Barbi; Corinna Greco; Simonetta Zupo; Anna Bertolaso; Maria Teresa Scupoli; Mauro Krampera; Paul Takam Kamga; Carlo M. Croce; Aldo Scarpa; Alberto Zamò

First line drug treatment of follicular lymphoma (FL) patients is followed by a highly variable disease-free time before relapse in about one third of patients. No molecular marker is able to predict efficiently the risk of relapse. We investigated the expression profile of microRNAs (miRNAs) by microarrays and of the tumor microenvironment by immunohistochemistry in 26 FLs and 12 reactive lymph nodes (rLN) as reference. Twenty-nine miRNAs were differentially expressed in FLs compared to rLNs and some of them discriminated grade 1 from 3a FLs. Both FLs and rLNs displayed molecular heterogeneity. FLs grouped into two clusters mostly driven by the tumor T-cell content. Among 21 drug-treated FL patients with an average follow-up of 13.5 years, eight cases relapsed. Twenty-six miRNAs discriminated between relapsed and non-relapsed FLs. Ten miRNAs also correlated with Foxp3+ cells number. Notably, Foxp3+ cells were significantly less in relapsed patients and lower Foxp3+ cell number associated with shorter time-to-relapse. Foxp3+ cells did not co-expressed follicular helper T-cell markers and were therefore classified as regulatory T cells rather than follicular regulatory T-cells. These findings introduce new knowledge about the relationship between miRNA alterations and infiltrating immune cells and show that Foxp3+ cells might be predictive of disease relapse.


Journal of Analytical Oncology | 2017

Knowledge and Behavior of Women on Cervical Cancer in the Northern Region of Cameroon

Armel Herve Nwabo Kamdje; Georges Kalgong; Paul Takam Kamga; Richard Simo Tagne; Jérémie Mbo Amvene; Charlette Nangue

Background : Cervical cancer is a major cause of women death worldwide. The reduction of the mortality and morbidity of this pathology depends on the early detection based on powerful suitable screening methods, that will lead to optimal treatment strategies. However in some rural region of developing countries, it is very difficult to get access to standard screening methods, alternative screening methods, cheaper and easy to handle are then useful. Objective : The aim of this work was to test the sensitivity and specificity of VIA (Visual inspection with acetic acid) and VILI (Visual inspection with lugol iodine) as a diagnostic test of cervical cancer compared to the Pap Smear, evaluating the feasibility in health formation in the North Cameroon region, of implementing epidemiological surveillance of cervical cancer based on early diagnosis using the VIA-VILI association Method : 309 women age 20 to 62 years were recruited in this study, 307 were included in the statistical analyzes. Each woman was screened for cervical cancer by a conventional Smear and visual inspection with acetic acid 5% and the lugol solution. Results : We found in our study a prevalence of precancerous lesions of cervix at 12.70%. The risks factors of cervical cancer identified are age, matrimonial status, age of first sexual intercourse and parity. The association of VIA and VILI showed a sensitivity, specificity, positive and negative predictive value respectively about 93.58%; 97.01%; 82.01%, 99.04%. Conclusion : Compared to PAP Smear, VIA or VILI could be used as an alternative screening methods for cervical cancer in developing countries, where it is difficult to access to more accurate test such as colposcopy and biopsy.


Mesenchymal Stromal Cells as Tumor Stromal Modulators | 2016

Mesenchymal Stem/Stromal Cell Trafficking and Homing

A.H. Nwabo Kamdje; L. Vecchio; P.F. Seke Etet; Paul Takam Kamga; Jean Marc Muller; Giulio Bassi; Erique Lukong; Raghuveera Kumar Goel; Mauro Krampera

Mesenchymal stem/stromal cells (MSCs) are adult multipotent stem cells which may reside as pericytes in various tissues and organs, where they may differentiate into specialized cells to replace dying cells and damaged tissues. These cells are commonly found at injury sites, but also in tumors, which are known to behave like “wounds that do not heal.” Herein, we discuss the mechanisms used by MSCs to migrate, home, and repair injured tissues, and we review a number of reports showing that the tumor microenvironment triggers plasticity mechanisms in MSCs to induce malignant neoplastic tissue formation, maintenance, and chemoresistance, as well as tumor growth. The antitumor properties and the therapeutic potential of MSCs are also discussed.


Cancer biology and medicine | 2017

Mesenchymal stromal cells’ role in tumor microenvironment: involvement of signaling pathways

Armel Herve Nwabo Kamdje; Paul Takam Kamga; Richard Tagne Simo; Lorella Vecchio; Paul Faustin Seke Etet; Jean Marc Muller; Giulio Bassi; Erique Lukong; Raghuveera Kumar Goel; Jérémie Mbo Amvene; Mauro Krampera

Collaboration


Dive into the Paul Takam Kamga's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge